Hospital de la Santa Creu i Sant Pau

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Director of the Internal Medicine Department and head of the Fibromyalgia and Chronic Fatigue Syndrome Functional Unit at the Hospital Sant Pau in Barcelona

Clinical Head of the Thoracic Surgery Department at the Hospital de la Santa Creu i Sant Pau in Barcelona, co-coordinator of the CASSANDRA lung cancer screening project and director of Integrated Research Projects in Thoracic Oncology at the Spanish Society of Pneumology and Thoracic Surgery (SEPAR)

Neurologist at the Memory Unit of the Neurology Service of the Hospital de la Santa Creu i Sant Pau in Barcelona and coordinator of the Study Group of Behavioural Neurology and Dementias of the Spanish Society of Neurology

Director of the Dermatology Department of the Hospital de la Santa Creu i Sant Pau and professor at the Autonomous University of Barcelona

Neurologist specialising in autoimmune and neuromuscular neurological diseases at the Hospital Sant Pau in Barcelona.

Specialist in Immunology at the Hospital de Sant Pau in Barcelona and secretary of the Spanish Society of Immunology.

Contents related to this centre
Tobacco

A study has analysed more than 100 environmental factors and their impact on the immune response. After studying about a thousand volunteers, its conclusions are that smoking is the factor that causes the most alterations in defences. While some changes are transient, others may remain for years after quitting. The results are published in the journal Nature.

Multiple sclerosis /

An international team, involving researchers from Hospital Clínic-IDIBAPS and the Multiple Sclerosis Centre of Catalonia (Cemcat), has identified for the first time a genetic variant related to the progression of multiple sclerosis. It is located near two genes that had not previously been linked to multiple sclerosis. According to Stephen Sawcer, co-lead author of the study, "understanding how the variant exerts its effects on the severity of multiple sclerosis will pave the way for a new generation of treatments that can prevent disease progression". The results are published in the journal Nature.

EM

A study of 89 patients has shown that the drug teriflunomide is able to delay the onset of multiple sclerosis symptoms in people whose MRI scans show early signs of the disease, even if they have not yet developed symptoms. The work has not yet been published in a scientific journal and its results have been shared at a meeting of the American Neurological Association.

sucralose

A study in mice has found that high doses of the sweetener sucralose can reduce the immune response and, under certain laboratory conditions, alter its action against infections or tumours. The results are published in the journal Nature.

microbiome

Two studies have found changes in the microbiome of patients affected by chronic fatigue syndrome. In particular, they have found a decrease in both butyrate and certain bacteria that produce butyrate. Butyrate is a factor related to the protection of the intestinal barrier and appears to play a role in the regulation of the immune system. Both papers are published in the journal Cell Host and Microbe.

sleep

A Swedish study has found an association between lack of sleep or poor quality sleep during adolescence and an increased risk of developing multiple sclerosis later in life. They put the relative increased risk at 40 %. The results are published in the Journal of Neurology, Neurosurgery and Psychiatry.

David Vetter

Bubble boy syndrome is a very serious condition caused by combined immunodeficiency. It is sometimes caused by certain mutations in the gene that codes for the Artemis protein. A phase I-II clinical trial has tested a gene therapy that adds a correct copy of the gene. The results are published in the journal NEJM.

alzhéimer

A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.

Vitiligo

A double clinical trial has analyzed the efficacy of ruxolitinib cream in treating depigmentation associated with vitiligo. The results are published in the New England Journal of Medicine.

beta-amiloide

Science magazine has published a report revealing multiple indications of fraud in one of the most cited publications on Alzheimer's disease. We explain what it means for the science that studies this disease.